Home » Newsletters » BioWorld Science

BioWorld Science

June 4, 2002

View Archived Issues

Potent dual MMP/TACE inhibitors designed by Novartis

Kagome presents novel hepatoprotectants

PDE inhibitors for use in hypertension, etc.

Piperazine-containing factor Xa inhibitors patented by Cor Therapeutics (Millennium)

Ajinomoto describes factor Xa-inhibitory benzodiazepines

New antimalarial compounds designed by Shionogi R&D team

Schering presents PDE5 inhibitors for erectile dysfunction

Histamine H3 receptor modulators and their use in sleep disorders, etc.

Biovail licenses Metformin GR from DepoMed

Bay-55-9837, a selective VPAC2 agonist, as a potential therapy for type 2 diabetes

First orally active, selective MCH receptor antagonist identified at Takeda

Discovery of potent, selective, nonsteroidal GR antagonists using 3-D pharmacophore design

Cyclophilin-binding compound with immunomodulating, antiasthmatic and antiinflammatory effects

Gastrointestinal safety of NCX-4016 demonstrated in humans

Superior GI tolerance of COX-189 compared to naproxen reported in healthy subjects

Aventis initiates Lovenox trial in patients with acute STEMI

AltaRex announces major directional change

Room-temperature Betaseron launched in U.S. for relapsing-remitting MS

NCX-1015 does not aggravate ischemia/reperfusion-induced gastric injury

Oryx to market and promote Corvert in Canada

Advectus collaborates with U. of N. Carolina on brain tumor drug development

Corixa files request for formal dispute resolution for Bexxar

Genzyme Transgenics announces name change

CPMP issues positive opinion for Xigris in severe sepsis

FDA approves Imagent for ultrasound imaging of the heart

Known antihypertensive drug shows benefit in normotensive rat model of stroke